Search
Search
Novel biotherapeutics, including bispecific and multispecific antibodies (bsAb, msAb), antibody-drug conjugates (ADCs), are revolutionizing biomedical therapies yet pose analytical challenges due to their sequence diversity, structural complexity, and susceptibility to various degradation pathways.
In this presentation, Ben Niu will showcase how his team has integrated advanced techniques such as automation and machine learning to achieve unprecedented mass spectrometry-focused sample handling capabilities and rapid turnover rates. These approaches deliver unmatched depth and breadth in understanding diverse molecular modalities within a condensed timeline.
Ben Niu
Principal Scientist, Discovery Biotherapeutics
Bristol Myers Squibb
Xiaoxi Zhang
Application Manager, Pharma & biopharma
Thermo Fisher Scientific